Low cutaneous follistatin expression is associated with striae gravidarum: A pilot study of the TGF-β/BMP signaling pathway.
Low levels of follistatin in skin may be linked to the development of striae gravidarum, but more research is needed to understand this relationship.
Where it sits
this study against the rest of the follistatin-344 corpusSummary and findings
This study measured the expression levels of follistatin (FST) in skin biopsies from four patients with striae gravidarum (SG) and six unaffected postpartum controls. FST expression was reduced by approximately 225.59-fold in SG lesional skin compared to non-SG control skin. The study aimed to explore the molecular mechanisms underlying SG.
Abstract
Striae gravidarum (SG) causes prominent cosmetic impairment and psychological distress, yet its underlying etiology and molecular mechanisms remain poorly characterized. Unraveling core molecular cascades of SG is critical for developing targeted therapeutics. In this study, we first screened differentially expressed genes among the TGF-β/BMP-related molecules in skin biopsies from four SG patients and six unaffected postpartum controls via TGF-β/BMP-focused PCR Array to prioritize candidate pathogenic genes. <i>F</i>ollistatin (<i>FST</i>) emerged as the most prominently downregulated candidate gene in SG, with expression reduced by approximately 225.59-fold in SG lesional skin versus non-SG control skin. We further validated the expression profiles of FST and core related molecules (TGF-β1, BMP4 and Smad3) using molecular assays. Quantitative analyses revealed consistent downregulation of all these molecules in lesional SG skin. Immunohistochemical staining was additionally applied to verify the tissue-level expression pattern of FST. Taken together, our results suggest that low cutaneous FST expression may be associated with the pathogenesis of striae gravidarum.
Background
Striae gravidarum (SG) is a condition that leads to cosmetic concerns and psychological distress, yet its molecular mechanisms are not well understood. Previous research has indicated a potential role of the TGF-β/BMP signaling pathway in skin conditions, but specific gene expressions related to SG have not been thoroughly investigated. This study aims to identify differentially expressed genes in SG to better understand its etiology and potential therapeutic targets.
Methods
The study utilized a TGF-β/BMP-focused PCR Array to screen for differentially expressed genes in skin biopsies. The population included four patients with SG and six unaffected postpartum controls. The expression of follistatin and related molecules was validated using molecular assays and immunohistochemical staining.
Results
Follistatin expression was reduced by approximately 225.59-fold in SG lesional skin compared to non-SG control skin. The study also reported consistent downregulation of TGF-β1, BMP4, and Smad3 in lesional SG skin. Not reported in abstract.
Interpretation
The significant reduction in follistatin expression may suggest a role in the pathogenesis of striae gravidarum, although the clinical significance of a 225.59-fold reduction is unclear without further context. The small sample size and lack of control for confounding variables limit the conclusions that can be drawn. This study adds to the understanding of molecular pathways involved in SG but requires larger studies for validation.
Key findings
- Follistatin expression reduced by approximately 225.59-fold in SG lesional skin versus non-SG control skin.
- TGF-β1, BMP4, and Smad3 also showed consistent downregulation in lesional SG skin.
- Not reported in abstract.
Limitations
- small sample size of n=4 SG patients and n=6 controls
- not a randomized controlled trial
- results may not be generalizable
- short follow-up period
- not reported in abstract